Adverum Biotechnologies Inc (NASDAQ:ADVM)
| 1.20 Delayed Data As of 3:59pm ET |  +0.01 / +0.84%Today’s Change | 0.53 Today|||52-Week Range 2.34 | +107.08% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $151.5M |
Company Description
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.
Contact Information
Adverum Biotechnologies, Inc. 100 Cardinal Way Redwood City California 94063 |
Employees
Shareholders
| Other institutional | 42.19% |
| Individual stakeholders | 4.43% |
| Mutual fund holders | 14.19% |
Top Executives
| Laurent Fischer | President, Chief Executive Officer & Director |
| Peter Soparkar | Chief Operating & Legal Officer |
| Linda M. Rubinstein | Chief Financial & Accounting Officer |
| Heikki Jouttijärvi | Senior VP & Head-Technical Operations |
| Bill Tan | SVP & Head-Global Clinical Operations |
